Abstract
Fidaxomicin (Fdx) constitutes a glycosylated natural product with excellent antibacterial activity against various Gram-positive bacteria but is only approved for Clostridioides difficile infections. Poor water solubility and acid lability preclude its use for other infections. Herein, we describe our strategy to overcome the acid lability by introducing acid stable S-linked glycosides. We describe the direct, diastereoselective modification of unprotected Fdx without the need to avoid air or moisture. Using our newly established approach, Fdx was converted to the single atom exchanged analogue S-Fdx, in which the acid labile O-glycosidic bond to the noviose sugar is replaced by the acid stable S-glycosidic bond. Studies of the antibacterial activity of a structurally diverse set of thioglycoside derivatives revealed high potency of acyl derivatives of S-Fdx against Clostridioides difficile (MIC range: 0.12–4 μg/mL) and excellent potency against Clostridium perfringens (MIC range: 0.06–0.5 μg/mL).
Supplementary materials
Title
Supporting Information
Description
Supplementary figures and tables, experimental procedures, compound characterization, crystallographic data, and NMR spectra of new compounds are provided in the Supplementary information file.
Actions
Title
DP4+_Calcluations
Description
Detailed procedures and results of DP4+ calculations are provided in the Supplementary information DP4+ file (SI_DP4+).
Actions
Supplementary weblinks
Title
Zenodo Data Set
Description
Additional data, such as the coordinate files for conformers of both epimers of the compounds 5a-C(11), 5a-C(13), 5a-C(15), 18e-C(11) (simplified and full molecule), 18e-C(13), 18e-C(15) and NMR data (raw data and additional 2-D NMR data) were deposited at zenodo and can be obtained free of charge via DOI: 10.5281/zenodo.10618934.
Actions
View